HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION JPMA to Closely Watch Clinical Research Bill to Decide Whether to Review All Ads
April 6, 2015
-
BUSINESS Sanofi Japan Sales Dip 7.6% on Generic Erosion though Plavix Grew
April 3, 2015
-
ACADEMIA Stop Use of SGLT-2 Inhibitors, NSAIDs in Elderly: Japan Geriatrics Society
April 3, 2015
-
BUSINESS Mochida Unveils New 3-Year Biz Targets, Price Revisions, Generic Penetration Weigh
April 2, 2015
-
BUSINESS Lupin Group’s Kyowa Sees Japan-India Collaboration as Key to Survival: Pres.
April 1, 2015
-
ACADEMIA CRPC Drugs Xtandi, Zytiga Neck-and-Neck in Key Opinion Leader Poll
April 1, 2015
-
BUSINESS Fujifilm to Buy US iPS Cell Manufacturer Cellular Dynamics
March 31, 2015
-
REGULATORY Otani, Ex-Number 2 at MHLW, Tapped as Aide to Chief of AMED
March 30, 2015
-
BUSINESS Pfizer Looking for Drug Discovery Partnerships with Domestic Drug Makers
March 30, 2015
-
REGULATORY Nonpartisan Group Launched to Push Biosimilar Use, Lawmaker-Sponsored Bill Eyed
March 27, 2015
-
BUSINESS Sovaldi, Oral, Interferon-Free Treatment, Approved for Chronic HCV Infection in Japan: Gilead Sciences
March 27, 2015
-
ORGANIZATION Applying Uniform Pricing Rule to Unprofitable but Essential Drugs Difficult: Kenporen Veep
March 26, 2015
-
BUSINESS 3-Bracket Pricing Rule for Generics Should Be Defended: Sawai Chairman
March 25, 2015
-
BUSINESS Takeda to Collaborate with ImmunoGen for ADC Technology
March 25, 2015
-
BUSINESS AZ Looks to Lead Industry in Immuno-Oncology Arena: Oncology Head
March 24, 2015
-
INTERVIEW Takeda Aims to Return to Growth Track in FY2016, Sales Head Confident in Takecab
March 23, 2015
-
BUSINESS Amgen Astellas Seeks Japan Approval of PCSK9 Inhibitor
March 23, 2015
-
ORGANIZATION FPMAJ Renews Call for Changing NHI Pricing Rules for Unprofitable Drugs with Great Medical Needs
March 20, 2015
-
REGULATORY Chuikyo OKs Quantitative Premium Calculation for Operating Profit Rates
March 19, 2015
-
BUSINESS MSD Revving Up Detailing on Rotavirus, Hepatitis B Vaccines, Eyes Public Immunization Program
March 18, 2015
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…